Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism
Arata Fukushima, Liyan Zhang, Alda Huqi, Victoria H. Lam, Sonia Rawat, Tariq Altamimi, Cory S. Wagg, Khushmol K. Dhaliwal, Lisa K. Hornberger, Paul F. Kantor, Ivan M. Rebeyka, Gary D. Lopaschuk
Arata Fukushima, Liyan Zhang, Alda Huqi, Victoria H. Lam, Sonia Rawat, Tariq Altamimi, Cory S. Wagg, Khushmol K. Dhaliwal, Lisa K. Hornberger, Paul F. Kantor, Ivan M. Rebeyka, Gary D. Lopaschuk
View: Text | PDF
Research Article Metabolism

Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism

  • Text
  • PDF
Abstract

A dramatic increase in cardiac fatty acid oxidation occurs following birth. However, cardiac hypertrophy secondary to congenital heart diseases (CHDs) delays this process, thereby decreasing cardiac energetic capacity and function. Cardiac lysine acetylation is involved in modulating fatty acid oxidation. We thus investigated what effect cardiac hypertrophy has on protein acetylation during maturation. Eighty-four right ventricular biopsies were collected from CHD patients and stratified according to age and the absence (n = 44) or presence of hypertrophy (n = 40). A maturational increase in protein acetylation was evident in nonhypertrophied hearts but not in hypertrophied hearts. The fatty acid β-oxidation enzymes, long-chain acyl CoA dehydrogenase (LCAD) and β-hydroxyacyl CoA dehydrogenase (βHAD), were hyperacetylated and their activities positively correlated with their acetylation after birth in nonhypertrophied hearts but not hypertrophied hearts. In line with this, decreased cardiac fatty acid oxidation and reduced acetylation of LCAD and βHAD occurred in newborn rabbits subjected to cardiac hypertrophy due to an aortocaval shunt. Silencing the mRNA of general control of amino acid synthesis 5-like protein 1 reduced acetylation of LCAD and βHAD as well as fatty acid oxidation rates in cardiomyocytes. Thus, hypertrophy in CHDs prevents the postnatal increase in myocardial acetylation, resulting in a delayed maturation of cardiac fatty acid oxidation.

Authors

Arata Fukushima, Liyan Zhang, Alda Huqi, Victoria H. Lam, Sonia Rawat, Tariq Altamimi, Cory S. Wagg, Khushmol K. Dhaliwal, Lisa K. Hornberger, Paul F. Kantor, Ivan M. Rebeyka, Gary D. Lopaschuk

×

Figure 3

Acetylation of peroxisome proliferator–activated receptor γ coactivator 1α, and expression of enzymes for triacylglycerol/ceramide synthesis in human neonatal hearts.

Options: View larger image (or click on image) Download as PowerPoint
Acetylation of peroxisome proliferator–activated receptor γ coactivator ...
(A–D and F) Representative immunoblots and analysis of peroxisome proliferator–activated receptor γ coactivator 1α (PGC1α) (n = 6/group), acetylated PGC1α (Ac-PGC1α, n = 8/group), and citrate synthase (CS, n = 6/group). (G) CS activity (n = 5/group). (E and H–K) Representative immunoblots and analysis of diacylglycerol acyltransferase 2 (DGAT2), adipose triglyceride lipase (ATGL), and serine palmitoyltransferase 1 and 2 (SPT1 or SPT2) (n = 6/group in H–K). All lanes were run on the same gel but were noncontiguous, except for ATGL and SPT1, which were from different gels for each group (hypertrophy/nonhypertrophied). Values represent mean ± SEM. *P < 0.05, 2-way ANOVA, comparing ages 21–100 days and 101–200 days in the same group. IgG-LC, antibody IgG light chain; PC, positive control from the heart lysate without incubation of antibody. White circles denote age of 21–100 days, and black circles denote age of 101–200 days.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts